[EU PEGS] Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release

[EU PEGS] Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release
Version:
21404

File Name/Number:
EU PEGS

Year:
2022

 

The clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory agents with distinct mechanisms-of-action (MOA) targeting novel antigens.